Key clinical point:Patients with type 2 diabetes who are treated with lixisenatide or sitagliptin are at no greater risk for heart failure than if...
Key clinical point: Empagliflozin reduced cardiovascular risk in patients with type 2 diabetes who were at high cardiovascular risk, making it the...
Key clinical point: The glucagon-like peptide 1 (GLP-1) receptor agonist lixisenatide does not increase the risk for cardiovascular problems in...
Key clinical point: Sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor used to lower blood glucose in patients with type 2 diabetes, was not...
